JP7023929B2 - キメラポックスウイルス組成物及びその使用 - Google Patents

キメラポックスウイルス組成物及びその使用 Download PDF

Info

Publication number
JP7023929B2
JP7023929B2 JP2019507161A JP2019507161A JP7023929B2 JP 7023929 B2 JP7023929 B2 JP 7023929B2 JP 2019507161 A JP2019507161 A JP 2019507161A JP 2019507161 A JP2019507161 A JP 2019507161A JP 7023929 B2 JP7023929 B2 JP 7023929B2
Authority
JP
Japan
Prior art keywords
nucleic acid
strain
virus
acid sequence
poxvirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019507161A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524131A5 (enExample
JP2019524131A (ja
Inventor
フォン，ユーマン
チェン，ナンハイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Publication of JP2019524131A publication Critical patent/JP2019524131A/ja
Publication of JP2019524131A5 publication Critical patent/JP2019524131A5/ja
Priority to JP2022017693A priority Critical patent/JP7395628B2/ja
Application granted granted Critical
Publication of JP7023929B2 publication Critical patent/JP7023929B2/ja
Priority to JP2023200433A priority patent/JP7631485B2/ja
Priority to JP2025016649A priority patent/JP2025072482A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019507161A 2016-08-09 2017-08-09 キメラポックスウイルス組成物及びその使用 Active JP7023929B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022017693A JP7395628B2 (ja) 2016-08-09 2022-02-08 キメラポックスウイルス組成物及びその使用
JP2023200433A JP7631485B2 (ja) 2016-08-09 2023-11-28 キメラポックスウイルス組成物及びその使用
JP2025016649A JP2025072482A (ja) 2016-08-09 2025-02-04 キメラポックスウイルス組成物及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662372408P 2016-08-09 2016-08-09
US62/372,408 2016-08-09
US201762519010P 2017-06-13 2017-06-13
US62/519,010 2017-06-13
PCT/US2017/046163 WO2018031694A1 (en) 2016-08-09 2017-08-09 Chimeric poxvirus compositions and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022017693A Division JP7395628B2 (ja) 2016-08-09 2022-02-08 キメラポックスウイルス組成物及びその使用

Publications (3)

Publication Number Publication Date
JP2019524131A JP2019524131A (ja) 2019-09-05
JP2019524131A5 JP2019524131A5 (enExample) 2020-09-17
JP7023929B2 true JP7023929B2 (ja) 2022-02-22

Family

ID=61163330

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019507161A Active JP7023929B2 (ja) 2016-08-09 2017-08-09 キメラポックスウイルス組成物及びその使用
JP2022017693A Active JP7395628B2 (ja) 2016-08-09 2022-02-08 キメラポックスウイルス組成物及びその使用
JP2023200433A Active JP7631485B2 (ja) 2016-08-09 2023-11-28 キメラポックスウイルス組成物及びその使用
JP2025016649A Pending JP2025072482A (ja) 2016-08-09 2025-02-04 キメラポックスウイルス組成物及びその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022017693A Active JP7395628B2 (ja) 2016-08-09 2022-02-08 キメラポックスウイルス組成物及びその使用
JP2023200433A Active JP7631485B2 (ja) 2016-08-09 2023-11-28 キメラポックスウイルス組成物及びその使用
JP2025016649A Pending JP2025072482A (ja) 2016-08-09 2025-02-04 キメラポックスウイルス組成物及びその使用

Country Status (11)

Country Link
US (2) US12084687B2 (enExample)
EP (1) EP3497209A4 (enExample)
JP (4) JP7023929B2 (enExample)
KR (3) KR102557818B1 (enExample)
CN (3) CN118853594A (enExample)
AU (2) AU2017311380A1 (enExample)
BR (1) BR112019002646A2 (enExample)
CA (1) CA3033512A1 (enExample)
MX (1) MX2019001672A (enExample)
RU (2) RU2757002C2 (enExample)
WO (1) WO2018031694A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150320799A1 (en) 2012-12-20 2015-11-12 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
WO2016144564A2 (en) 2015-02-25 2016-09-15 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
CN107847534B (zh) 2015-04-17 2022-10-04 纪念斯隆凯特琳癌症中心 Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用
IL261321B2 (en) 2016-02-25 2023-12-01 Memorial Sloan Kettering Cancer Center Recombinant MVA or MVADELE3L expressing human FLT3L and their use as immunotherapeutic agents against solid tumors
SG11201807051VA (en) 2016-02-25 2018-09-27 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
CN118853594A (zh) * 2016-08-09 2024-10-29 希望之城 嵌合痘病毒组合物及其用途
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
WO2018209315A1 (en) 2017-05-12 2018-11-15 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
EP3664841A1 (en) * 2017-08-11 2020-06-17 City of Hope Oncolytic virus expressing a car t cell target and uses thereof
AU2019209432A1 (en) 2018-01-22 2020-08-06 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for CAR T cells
WO2019165237A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
MX2020009262A (es) * 2018-03-07 2021-01-08 Transgene Vectores de parapoxvirus.
WO2019213173A1 (en) * 2018-04-30 2019-11-07 City Of Hope Neural stem cell compositions including chimeric poxviruses for cancer treatment
CN116162654A (zh) 2018-09-15 2023-05-26 纪念斯隆凯特琳癌症中心 用于癌症免疫疗法的重组痘病毒
CN113583977B (zh) * 2020-04-30 2025-06-06 杭州康万达医药科技有限公司 可受微小rna调控的分离的重组溶瘤痘病毒及其应用
GB2614309A (en) 2021-12-24 2023-07-05 Stratosvir Ltd Improved vaccinia virus vectors
WO2023213763A1 (en) * 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
CN120380015A (zh) 2022-08-18 2025-07-25 特兰斯吉恩公司 嵌合痘病毒
AU2024280931A1 (en) * 2023-05-26 2025-11-27 Probiogen Ag Rapid selection system for the generation of recombinant enveloped viruses
WO2025184411A1 (en) 2024-02-27 2025-09-04 Calidi Biotherapeutics (Nevada), Inc. Serum-resistant eev viruses and uses thereof
CN120718864B (zh) * 2025-08-28 2025-11-28 山东农业大学 一种高度不成熟鸭坦布苏病毒及其培养方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT406376B (de) * 1998-01-16 2000-04-25 Immuno Ag Chimäres poxvirus enthaltend eine retrovirale vektorkomponente
US7067251B2 (en) 2000-03-28 2006-06-27 University Of Rochester Methods of directly selecting cells expressing inserts of interest
DE60314541T2 (de) * 2002-11-25 2008-02-28 Bavarian Nordic A/S Mindestens zwei ati promotoren enthaltendes rekombinantes pockenvirus
SG179291A1 (en) * 2003-06-18 2012-04-27 Genelux Corp Modified recombinant vaccinia viruses and other microorganisms, uses thereof
EP2426142A3 (en) 2006-10-16 2012-06-13 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
CA2705873C (en) * 2007-11-19 2012-06-12 Philippe Erbs Poxviral oncolytic vectors
CA2795695A1 (en) 2010-04-09 2011-10-13 The University Of Tokyo Microrna-controlled recombinant vaccinia virus and use thereof
WO2012142529A2 (en) 2011-04-15 2012-10-18 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
CN104768567B (zh) 2012-05-18 2017-07-11 奥塔哥创业有限公司 用于伤口愈合的联合治疗和组合物
CN118853594A (zh) * 2016-08-09 2024-10-29 希望之城 嵌合痘病毒组合物及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Japan J Microbiol, 1968, Vol.12, No.4, pp.495-504
Virology, 1997, No.229, pp.193-200

Also Published As

Publication number Publication date
CA3033512A1 (en) 2018-02-15
BR112019002646A2 (pt) 2019-10-08
MX2019001672A (es) 2019-06-06
AU2023270200A1 (en) 2024-01-25
KR20230113832A (ko) 2023-08-01
RU2757002C2 (ru) 2021-10-08
KR20250067190A (ko) 2025-05-14
US20190218522A1 (en) 2019-07-18
RU2019106319A (ru) 2020-09-17
CN118834840A (zh) 2024-10-25
KR20190038626A (ko) 2019-04-08
JP2019524131A (ja) 2019-09-05
AU2017311380A1 (en) 2019-03-28
JP2022065034A (ja) 2022-04-26
US12084687B2 (en) 2024-09-10
KR102557818B1 (ko) 2023-07-20
CN110199018B (zh) 2024-06-07
JP2024026191A (ja) 2024-02-28
EP3497209A4 (en) 2020-07-29
CN110199018A (zh) 2019-09-03
EP3497209A1 (en) 2019-06-19
JP7395628B2 (ja) 2023-12-11
RU2021128158A (ru) 2022-04-07
RU2019106319A3 (enExample) 2021-03-17
JP2025072482A (ja) 2025-05-09
US20250084384A1 (en) 2025-03-13
WO2018031694A1 (en) 2018-02-15
JP7631485B2 (ja) 2025-02-18
CN118853594A (zh) 2024-10-29

Similar Documents

Publication Publication Date Title
JP7023929B2 (ja) キメラポックスウイルス組成物及びその使用
JP7621053B2 (ja) キメラ抗原受容体に関する方法および組成物
US9605074B2 (en) Multifunctional nanobodies for treating cancer
Levitzki et al. Signal transduction therapy of cancer
TW202023629A (zh) 用於調節單核球及巨噬細胞發炎表型之組合物及方法以及其免疫療法用途
ES2905160T3 (es) Inhibidores selectivos de la isoforma TGFBeta1 y utilización de los mismos
JP7239463B2 (ja) がん免疫療法のための組成物および方法
JP2022527081A (ja) 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変ｔ細胞（ｃａｒ－ｔ）
US12383588B2 (en) Zika virus treatment of CD24-positive tumors and diseases associated with abnormal T cell activation and treating or preventing Zika virus infections
US20230227549A1 (en) Oncolytic virus compositions and methods for the treatment of cancer
CN119816313A (zh) 含有抗人表皮生长因子受体2（her2）嵌合抗原受体（car）的自然杀伤细胞的给药方法
WO2018039332A1 (en) Immunoswitch nanoparticles for reprogrammed t cell responses
US20230147832A1 (en) Oncolytic virus compositions including il-15 complex and methods for the treatment of cancer
Wang et al. Peptide-based CAR-NK cells: A novel strategy for the treatment of solid tumors
US20210052660A1 (en) Neural stem cell compositions including chimeric poxviruses for cancer treatment
US20250186520A1 (en) Oncolytic virus compositions and methods for the treatment of cancer
US10335481B2 (en) Gene-modified measles virus for tumor treatment use
US20240132887A1 (en) Protein arginine methyltransferase 9 inhibitors and methods of use
US20250313648A1 (en) Binders of Chondroitin Sulfate Proteoglycan (CSPG4) Polypeptides
WO2025221781A2 (en) Chimeric antigen receptors targeting fgfr4 and/or cd276 and use thereof for the treatment of cancer
WO2024204685A1 (ja) 癌の治療および／または予防のための医薬組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200807

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200807

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210907

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220111

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220209

R150 Certificate of patent or registration of utility model

Ref document number: 7023929

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250